z-logo
open-access-imgOpen Access
Familiáris myelodysplasiás szindróma és akut myeloid leukaemia klinikai és genetikai háttere
Author(s) -
Péter Attila Király,
Krisztián Kállay,
Dóra Marosvári,
Gábor Benyó,
Anita Szőke,
Judit Csomor,
Csaba Bödör
Publication year - 2016
Publication title -
orvosi hetilap
Language(s) - Hungarian
Resource type - Journals
SCImago Journal Rank - 0.176
H-Index - 21
eISSN - 1788-6120
pISSN - 0030-6002
DOI - 10.1556/650.2016.30375
Subject(s) - cebpa , medicine , myeloid leukemia , myelodysplastic syndromes , myeloid , leukemia , germline mutation , malignancy , runx1 , cancer research , immunology , mutation , genetics , haematopoiesis , gene , biology , stem cell , bone marrow
Myelodysplastic syndrome and acute myeloid leukaemia are mainly sporadic diseases, however, rare familial cases exist. These disorders are considered rare, but are likely to be more common than currently appreciated, and are characterized by the autosomal dominant mutations of hematopoietic transcription factors. These syndromes have typical phenotypic features and are associated with an increased risk for developing overt malignancy. Currently, four recognized syndromes could be separated: familial acute myeloid leukemia with mutated CEBPA, familial myelodysplastic syndrome/acute myeloid leukemia with mutated GATA2, familial platelet disorder with propensity to myeloid malignancy with RUNX1 mutations, and telomere biology disorders due to mutations of TERC or TERT. Furthermore, there are new, emerging syndromes associated with germline mutations in novel genes including ANKRD26, ETV6, SRP72 or DDX41. This review will discuss the current understanding of the genetic basis and clinical presentation of familial leukemia and myelodysplasia.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom